Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Migraine. According to GlobalData, Phase II drugs for Migraine have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Prabotulinumtoxin A biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Prabotulinumtoxin A biosimilar overview
Prabotulinumtoxin A (Nabota) is a biosimilar of clostridium botulinum A toxin. It is a protein produced by the bacterium Clostridium botulinum. It is formulated as injection powder solution for intradermal and intramuscular route of administration. Nabota is indicated for muscle spasticity, and blepharospasm (eyelid spasms).
It is under development for the treatment of blepharospasm, sleep bruxism, gastroparesis and spasmodic torticollis (cervical dystonia), unspecified musculoskeletal disorders (benign masseteric hypertrophy), cervical dystonia and as preventive treatment of episodic, chronic migraine and post-traumatic stress disorder (PTSD). The drug candidate is an injectable 900 kDa purified botulinum toxin type A complex. It is administered through intramuscular and intradermal routes as a powder for solution.
AEON Biopharma overview
AEON Biopharma, formerly Alphaeon Corp, is a biopharmaceutical company that develops drugs for debilitating medical conditions. It is headquartered in Newport Beach, California, the US.
For a complete picture of Prabotulinumtoxin A biosimilar’s drug-specific PTSR and LoA scores, buy the report here.